A Study of Serum Visfatin Levels and Its Relationship with Body Mass Index in Women with Polycystic Ovarian Disease: A Cross Sectional study

Dharani, M (2020) A Study of Serum Visfatin Levels and Its Relationship with Body Mass Index in Women with Polycystic Ovarian Disease: A Cross Sectional study. Masters thesis, Madras Medical College, Chennai.


Download (3MB) | Preview


BACKGROUND: Polycystic ovarian disease is one of the most common gynaecological endocrine disorder affecting 6-10% of women in reproductive age group. It is one of the most common cause of anovulatory infertility. Obesity and Insulin resistance are interlinked in the pathogenesis of polycystic ovarian disease and hence these patients are more prone for metabolic syndrome and cardiovascular events. About 50% of women with Polycystic ovarian disease are found to be obese, especially visceral adiposity is found to be common in these patients. The prevalence of Insulin Resistance, Metabolic syndrome and cardiovascular risks in Polycystic ovarian disease are found to be higher in patients with increased BMI. Visfatin, is a recently discovered adipocytokine secreted preferentially in the visceral adipose tissue. It plays an essential role in number of biological processes such as inflammation, immunity, insulin resistance, endothelial cell dysfunction and angiogenesis. It also has insulin mimicking action and can serve as a proinflammatory mediator and immunomodulator. Visfatin also activates Nuclear Transcription factor NT F – KB and Metalloproteinases 2/9 in vascular endothelial cells and increase the risk of cardiovascular events. Several studies have shown that serum visfatin levels may predict the occurrence of metabolic syndrome, type 2 diabetes and cardiovascular events, and hence it can be used as a predictor of severity of insulin resistance and hence as a biomarker for treatment of polycystic ovarian disease. AIM OF THE STUDY: To determine whether serum visfatin levels are elevated in women with Polycystic ovarian disease and to find its relationship with Body Mass Index. OBJECTIVES: 1.To determine Serum Visfatin levels in women with newly diagnosed Polycystic ovarian disease. 2.To estimate the Body Mass Index. 3.To compare Serum Visfatin levels of non-obese and obese PCOD patients. MATERIALS & METHODS: It is a cross sectional study consisting of forty subjects who are newly diagnosed with PCOD in the age group of 18 to 40 years and another forty normal subjects of the same age group without PCOD. Serum Visfatin levels were assayed using the commercially available human visfatin ELISA kit using a Human Visfatin sandwich ELISA technique for both the study groups. The Body Mass Index using weight and height and Homeostasis Model Assessment-Insulin Resistance using fasting glucose and insulin levels are calculated. RESULTS: In my study, the BMI, the insulin resistance and the serum visfatin levels were estimated and compared in patients with PCOD and normal controls. Serum visfatin levels are correlated with BMI and Insulin Resistance in cases and controls. The results of my study show that serum visfatin levels are found to be elevated in women with PCOD than the normal control subjects and serum visfatin levels are found to be positively correlated with Insulin Resistance and Body Mass Index. CONCLUSION: The results showed a significant increase in the values of serum visfatin in the PCOD subjects than in the control subjects. The levels are more among obese cases compared with non-obese cases. The serum visfatin levels have significant positive correlation with BMI and Insulin Resistance.The increase in visfatin may be associated with obesity and Insulin Resistance in PCOD.

Item Type: Thesis (Masters)
Additional Information: 201715001
Uncontrolled Keywords: PCOD, Diabetes mellitus, Visfatin, Insulin resistance.
Subjects: MEDICAL > Physiology
Depositing User: Subramani R
Date Deposited: 30 Jan 2021 16:37
Last Modified: 01 Mar 2021 03:31
URI: http://repository-tnmgrmu.ac.in/id/eprint/13481

Actions (login required)

View Item View Item